Anavex Life Sciences Corp (AVXL)

[falconer66a]

They know, as do we.

I think Big Pharma is quite aware of what Anavex can do and are strategically doing what they can to delay and deny it's existence.

Surely, at least the first portion of this statement is true. They can read the same studies on the Anavex sigma-1 receptor agonists that we (and Dr. Hagerman) have. They are online, in the public domain; not hidden at all. No beans about it.

More important is how anyone will respond to learning of Anavex science. Most, not well trained in cytology or molecular biology, will summarily dismiss the data. Just too good to be true, effectively and safely dealing with a variety of CNS diseases that conventional drugs cannot. “Sure, a simple little molecule diffuses across the blood-brain barrier, gets into neurons, attaches to a particular resident protein, whereafter all sorts of healthful and restorative processes take place. Get real.”

Well, because they can see the biology, Big Pharma people have gotten real. They see the safety and validity of the mechanisms of action (MOAs) of blarcamesine just as well as those of us here (and Dr. Hageman). There’s nothing mystical or magical at play; just unique, proprietary biochemistry.

Which, then, raises the question of the second half of the statement. Can or will Big Pharma somehow thwart the eventual approval of blarcamesine, by either the US Food and Drug Administration (FDA), or, down under, the Australian Therapeutic Goods Administration (TGA)? Specifically, how might that be accomplished, after profoundly safe and effective human trials data are produced? When the girls in the Rett trial demonstrate therapeutic results of statistically-validated safety and efficacy, how will Big Pharma (or anyone else) keep the drug from being approved (in at least two countries)?

It will be even tougher after the Parkinson’s disease dementia trial data are released to the public. Then, even stronger and utterly conclusive will be the Alzheimer’s data; again in at least two different countries.

If Aduhelm can get approved with such meager outcomes data, with very severe and frequent adverse events, after good trial results appear there doesn’t seem to be anything that could keep blarcamesine off pharmacy shelves. But a matter of time; for the three blarcamesine clinical trials to conclude.